Synopsis

Trial leads are used to evaluate response to neuromodulation therapies prior to a definitive implantation. After the trial period, currently available leads require removal and replacement with a permanent lead. However, successful trial periods do not necessarily predict the long term success of a permanent implant 1,2. To reduce the burden of transitioning from a trial lead to a permanent lead, we developed a fully needle-implanted helical wire structure electrode which facilitates a trial period, which may be followed by a straightforward conversion to chronic therapy through either: 1) electrode-augmented transcutaneous stimulation, or 2) attachment to implanted pulse generators as demonstrated in a rodent sciatic nerve model.

Disclosures

This project is supported by Neuronoff Inc., NIH 1U18EB029251-01 Grant, and the DARPA EEI program. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily
endorsed by the Department of Defense or the National Institutes of Health. DL, SK, DV, JW, KG, AH, KAL, SN, MF, and AS are employed by and/or own equity in Neuronoff, Inc.

Jack Wragan

Neuronoff, Inc.

Appearances